I.

Introduction
Endophthalmitis is an infection that occurs as a result of seeding of

organisms into the interior of the eye following surgery (postoperative),
trauma (post-traumatic) or an infection elsewhere in the body (endogenous).
While the general rate of endophthalmitis has remained somewhat constant
over the past several years, the increased use of intravitreal injections for
the treatment of various degenerative and inflammatory ocular diseases, as
well as the growing number of invasive ocular surgeries, may create a
clinical environment in which organisms have a greater opportunity to infect
the eye. Endophthalmitis cases can be treated successfully if properly
managed, and useful vision can be retained. However, in severe cases of
bacterial endophthalmitis, significant vision loss can occur rapidly, despite
prompt and proper treatment.

Endophthalmitis is an inflammatory condition of the intraocular cavities
(ie, the aqueous and/or vitreous humor) usually caused by infection.
Noninfectious (sterile) endophthalmitis may result from various causes such
as retained native lens material after an operation or from toxic agents.
Panophthalmitis is inflammation of all coats of the eye including intraocular
structures.

The 2 types of endophthalmitis are endogenous (ie, metastatic) and
exogenous. Endogenous endophthalmitis results from the hematogenous
spread of organisms from a distant source of infection (eg, endocarditis).
Exogenous endophthalmitis results from direct inoculation of an organism
from the outside as a complication of ocular surgery, foreign bodies, and/or
blunt or penetrating ocular trauma.

1 | Page

Endogenous endophthalmitis is rare, occurring in only 2-15% of all
cases of endophthalmitis. Average annual incidence is about 5 per 10,000
hospitalized patients. In unilateral cases, the right eye is twice as likely to
become infected as the left eye, probably because of its more proximal
location to direct arterial blood flow from the right innominate artery to the
right carotid artery. Since 1980, candidal infections reported in IV drug users
have increased. The number of people at risk may be increasing because of
the spread of AIDS, more frequent use of immunosuppressive agents, and
more invasive procedures (eg, bone marrow transplantation).

Most cases of exogenous endophthalmitis (about 60%) occur after
intraocular surgery. When surgery is implicated in the cause, endophthalmitis
usually begins within 1 week after surgery. In the United States,
postcataractendophthalmitis is the most common form, with approximately
0.1-0.3% of operations having this complication, which has increased over
the last 3 yearsAlthough this is a small percentage, large numbers of
cataract operations are performed each year making the chances that
physicians may encounter this infection higher. Endophthalmitis may also
occur after intravitreal injections, although this risk in an analysis of over
10,000 injections is estimated at 0.029% per injection.

Posttraumatic endophthalmitis occurs in 4-13% of all penetrating
ocular injuries. Incidence of endophthalmitis with perforating injuries in rural
settings is higher when compared with nonrural settings. Delay in the repair
of a penetrating globe injury is correlated with increased risk of developing
endophthalmitis. Incidence of endophthalmitis with retained intraocular
foreign bodies is 7-31%.

2 | Page

An association appears to exist between the developments of
endophthalmitis in cataract surgery and age greater than or equal to 85
years.

Pseudo means false or pretending to be somethig it is not. Phakia
means the condition of having a lens in the eye. So, pseudo--phakia means
having a lens in the eye BUT it isn't your own normal lens. It is a man made
lens that has been implanted during cataract surgery to replace the lens the
surgeon has removed.
Diabetic retinopathy is retinopathy damage to the retina) caused by
complications of diabetes, which can eventually lead to blindness. [It is an
ocular manifestation of diabetes, a systemic disease, which affects up to 80
percent of all patients who have had diabetes for 10 years or more. Despite
these intimidating statistics, research indicates that at least 90% of these
new cases could be reduced if there was proper and vigilant treatment and
monitoring of the eyes. The longer a person has diabetes, the higher his or
her chances of developing diabetic retinopathy.

Our group chose this case of Endophthalmitis OP, Pseudophakia OU,
DM retinophaty as a subject of our case presentation because the group is
concerned about the occurrence of the disease which continues to cause
significant number or rate of disease which is very common in both man and
women. And to also enhance our knowledge concerning of its clinical
manifestations, possible causes, cure and prevention, and among others.
This pertinent knowledge will eventually become an indispensable tool that
can be shared to others and will never go out of style. As a future nurses, it is
imperative to learn new techniques in modern science in order to develop
skills that would benefit the medical world. This learning prospective must be

3 | Page

II. Perform physical assessment on client’s condition to attain baseline data. OD Pseudophabia OU DM Retinopathy to apply such knowledge and learning for optimum level of nursing care practice. state -of –the. Specific Objectives:  To assess the condition of the patient by establishing rapport. manifestations and other things connected to the condition to help the health care providers to diagnose the real condition properly. gather all vital information and determine client’s past and present health history. 4 | Page .conveyed to future generations and develop innovative techniques.  To know the different signs and symptoms.art technology that caters the modern man. Objectives General Objective: The case study aims to acquire information about Endopthalmitis .

Palanan. Nursing History BIOGRAPHICAL DATA Name : Patient X Age : 53 Gender : Male Civil Status : Widow Address : Brgy.  To be able to apply different nursing intervention on how to help them lessen their sufferings about their condition. 1960 Hospital : Ospital ng Makati Date of Admission : January 17. willingness to 5 | Page . To plan on how to care patients and plan managements for their condition regarding to this kind of case. 2014 Date of Interview : February 3. 2014 Reliability : 90% Source of information : Patient Criteria for reliability : A.45% =40% B. Level of consciousness of interviewee condition. Extent of data gathered demographics. Makati Nationality : Filipino Religion : Roman Catholic Birthdate : November 13. III. history habits .

and the symptoms persist.30% = 25% Chief Complaint: Redness OD PRESENT HISTORY: Patient known case of Endopthalmitis. According to the patient he drinks everyday and always present in their drinking session with friends. No consultation was done. Completeness of correlating facts of transpiring events . In the late 1990’s the patient was diagnosed with hypertension and start taking medication such as Lozartan. Which he believes he inherit it with his mother who died also with the same case. He starts smoking at the early age of 17 and smokes approximately 1 to 2 packs per day. OD which was increasing in size. He was only 17 years old that time. What he does is he crashed garlic eaten and chewed raw. He was diagnosed with Diabetes Mellitus. OU T/C DM retinopathy OU. He was admitted in a private hospital but he took the medication regimen only for 3 months and did not come back for 6 | Page .disclose info – 25% = 25% C. In the year 2000 he was diagnosed with PTB and treated only for 3 months. OD associated with greenish discharges. the current alcoholic drinks that is well known in his time. PAST HISTORY: In the year 1978 the patient met a jeepney accident and survived. 4 days prior to admission patient noted redness. In the year 1994 the patient was rushed in Trese Martires Hospital for loss of consciousness and prior to that incident he was complaining of blurring of vision and dizziness. From that time he’s taking OHA (Oral Hypoglycemic Agent) such as metformin and clevencamide to lower his sugar level. As the patient approach into his manhood stage he loves alcoholic drinks such as gin. Patient verbalizes he only takes insulin when he’s admitted in the hospital. There are times that the patient was very worried for he has no enough money to buy his medication if his blood pressure rises. There was also rate of severity. 1 day prior to admission the patient decided to consult medical advice. OD Pseudophakia. As his condition persist he was in and out in the Philippine General Hospital from time to time if it’s not because of diabetes then it is hypertension.

Last year November 2013 the patient doesn’t mind the blurring of vision because he understands that it is one of sign and symptoms of his condition which is the Diabetes Mellitus until his lost his right eye vision. He recalls all his vices when he was in his young age and verbalizes that “ Hanggat hindi ka sinisinggil ng katawan mo hindi ka tititgil sa bisyo mo”.follow up check up. On the same year the patient had undergone cataract surgery for both eyes. And then his left eye starts to blurred and lost the ability to see. In the recent year in 2011 the patient suffered from a mild stroke and he recovers. In the year 2012 he decided to stop smoking and drinking alcohol beverages. FAMILY GENOGRAM Diabetes Mellitus Hyper Rheumatic Fever and Hypertensi on Diabetes Mellitus and Hypertension Diabetes Mellitus 7 | Page Father Mother Brother Patient Decease d .

8 | Page .

He’s a drinker and drinks gin Pattern everyday. Diet : DM Diet Weight: 59 kilograms INTERPRETATION Ineffective health maintenance Nurse’s Pocket Guide Edition 12 Imbalanced nutrition: less than body requirements Nurse’s Pocket Guide Edition 12 . He exercises n and everyday. vegetables and chicken. Health Perceptio But still. Still he drinks 58 glasses of water. During his hospitalization. Before he got hospitalized. Pattern he had a good appetite and had no problem swallowing food. He also added that he is taking vitamins such as B Complex.IV. He is a smoker and Health Managem smokes 1 to 2 packs per day. he is not in a good state and he is uncomfortable of the environment. He wants to go back to his normal daily life because he can’t stand the fact that he is staying in the hospital. he only consumed what kind of diet the physician orders. he is performing a normal daily activity. he cannot eat the food he prefers to eat but the desired food for his nutrition because of his condition. Nutrition The patient states that he and consumes 1 cup of rice every Metabolic meal. GORDON’S FUNCTIONAL HEALTH PATTERN FUNCTION HEALTH PATTERN I II 9 | Page BEFORE HOSPITALIZATION According to the patient. He stated too that he and his family usually eat fish. He drinks water at least 5-8 glasses a day and whenever she wants to drink. He starts smoking at the early age of ent 17. He is taking DURING HOSPITALIZATION According to the patient. his condition was not good because of the redness in his right eye. Now that he is admitted in the hospital. He starts drinking alcoholic beverages at the age of 17.

Once or twice According to the patient. He doesn’t have any difficulty in Feces . defecating. he doesn’t feel difficulty in a day. He is doing the regular exercise but he walks and strolls in his neighbourhood. according to him. Weight: 59 kilograms Height: 5’7 III Eliminati on pattern Before being hospitalized. Readiness for enhanced urinary elimination H doesn’t have any difficulty in defecating and urinating.Odor: Foul Odor IV Activity and exercise pattern 10 | P a g e Height: 5’7 According to the patient.Texture: Not stated frequently.his maintenance medication for Hypertension which is Lozartan and Metformin and Clavenocamide for Diabetes Mellitus.Odor: Foul Odor .Consistency: Cloudy . he can only perform minimal movements because of unfamiliar environment.Color: Light Yellow .Color: Not stated urinating and he urinates . Before Nurse’s Pocket Guide Edition 12 .Color: Yellow . Urine .Consistency: Clear . he regularly defecates. In their house he can perform his activities and Impaired physical mobility Urine . he regularly finishes his daily routine despite the condition of his eyes.Amount: Scanty urine 20cc/hour Nurse’s Pocket Guide Edition 12 During hospitalization.

sitting. He routinely read newspaper and listens to the radio every morning. Disturbed Sensory Perception Nurse’s Pocket Guide Edition 12 . During hospitalization. In addition to that. he answers us clearly. He is focused on what we are talking.hospitalization. Sometimes the patient has a difficulty in memory and remembering things. people and past events. daily living because he memorizes the setting and placement of things respectively. taking a bath. change of clothes. He has a difficulty in seeing things because he lost his vision in his right eye and his left eye slowly by slowly starts to blur. He uses reading glasses whenever he reads newspaper. He is assertive all throughout the interview. still he has difficulty in his sense of sight. He recalls when he was still a kid he’s fun of karate. and any other movement on his own. getting up from bed. V Cognitive perceptu al pattern 11 | P a g e The patient can hear clearly. he can perform his daily activities.

He stated Selfthat he is feeling he wants to talk and he loves to perceptio greet people. He’s but he knows he can concept only silent and hot tempered when surpass this trial and can pattern. Nurse’s Pocket Guide Edition 12 . he sleeps at least 4 hours and waking from time to time. Most of the time. 12 | P a g e Disturbed sleep pattern Nurse’s Pocket Guide Edition 12 Readiness for enhanced self concept. and he feels he is a burden to his children. During hospitalization. still the same. Because of his age his sleeping hours at night was reduced. go home. before hospitalization. Selfwell known in their barangay. He worries his children are not listening to about the hospital billing him. he is a talkative person. He doesn’t take a nap at noontime because according to the patient either he’ll have a difficulty to sleep at night or no sleep at all.VI VII Sleeprest pattern According to the patient. The patient stated that his character of talkative is According to the patient. he can’t sleep well because time to time the nurse is giving him his eye drop medication. He stated that he is depressed and loses hope n.

According to the patient. he and his late wife are using family planning. He stated that care of him. The minimum he earns in children are irritable and pedicab driving is 300. there would be no changes because of his condition. Ineffective role performance Nurse’s Pocket Guide Edition 12 IX 13 | P a g e According to him. he is the hospital his children living with his two children and are the ones taking good granddaughter. His children mostly all families are undergoing admit that they are having financial problem like their family. Sometimes to his family needs he drives because of stress and pedicab to come up to their daily financial insufficiency his budget. speak not so good words towards him. Sexuality reproduc tive pattern. a hard time who’s the one He is a welder before and to look out for him in the because his income is insufficient hospital. Ineffective sexual pattern Nurse’s Pocket Guide Edition 12 . now that he is admitted in According to the patient. He is widowed for almost 7 years.VIII Role relations hip pattern According to the patient.

when he is stressed. According to the patient. Valuebelief pattern According to the patient.X XI Coping stress tolerance pattern According to the client. The patient states that she believes in God and he knows he can surpass it. And when he’s worried he seeks God’s presence for he finds peace and feels stress relieved. He trusts his life to God. he can’t manage stress properly because he is thinking of different things. he is Roman Catholic. When he’s worried he always think that he can surpass it through God. And he can attend the Sunday mass when he recovers. He is attending mass every week. 14 | P a g e Ineffective coping Nurse’s Pocket Guide Edition 12 Readiness for spiritual well being Nurse’s Pocket Guide Edition 12 . In the past 2 years of he feels sad because he is in and out in the hospital and he worries so much about the financial matter. he go to church every Sunday. he usually releases it by praying to God.

Respiratory System No significant finding. Gastrointestinal System No significant finding. Review of Systems EENT “ Masakit ang mata ko “ “Hindi na makakita ang kanan kong mata” Integumentary System No significant finding. Genitourinary System “ ihi ako ng ihi “ Nervous System “Nahihilo ako dahil sa kundisyon ng mata ko” “Nahihirapan akong makatulog” 15 | P a g e .V. Muscoskeletal System No significant finding.

conscious and coherent. 2014 Time: 10:30 AM General survey: The patient is awake. Normal (+) smooth Texture: Smooth Turgor: skin quickly returns to its original shape.VI. 16 | P a g e Normal Skin quickly returns to original shape Normal . patient is also cooperative . The initial vital signs were taken as follows: Height: Weight: BMI: Temperature: Heart Rate: Respiratory Rate: Blood Pressure: Organ/ System Skin 173 cm 59 kg 17. patient appears slightly pale and weak.35 – Under weight 37.2 C 76 bpm 20 cpm 140/100 mmHg Technique Inspection Palpation Normal Findings Color: Pinkish Actual Findings Color: Pale Moisture: Moist (+) moist Interpretati on Abnormal: May indicate decrease in blood flow due to lack of sleep. Upon interview. Physical Assessment: Date: February 3.

Due to the inflammation.Hair Inspection Nails Inspection Temperature: warm Even distribution Color: Black Color: Pinkish Contour: slightly curved or flat Capillary Refill: 1-3 secs Head Eyes (+)warm Normal Evenly distributed Color: Black Normal Color: Pinkish Normal Contour: flat Normal Capillary Refill: 2 secs Normal Inspection Inspection Normal Symmetrical facial feature Symmetrical facial feature Eye lids: (-) lesion (-)redness Eye lids: (-) lesion (+)redness (-) periorbital edema (-) periorbital edema Normal visual acuity Right: (unable to visualize) Left: (able to visualize but blurred) Conjunctiva: Pinkish in color Sclerae: white or buffy Conjunctiva: Red in color (right) Sclerae: Red (Right) Yellowish (Left) 17 | P a g e Normal Due to eye infection Normal Due to the inflammation. Due to eye irritation Due to eye irritation Due to infection .

Palpation Eyelids: (-) Masses Ears Nose Mouth Inspection Inspection Inspection Palpation Eyelids: (-) Masses Normal (-) discharges (-) discharges Normal (-) lesions (-) lesions Normal (-) nodules (-) nodules Normal (-) redness (-) redness Normal Symmetricall y aligned Symmetricall y aligned Normal (-) discharge (-) discharge Normal (-) flaring of nares Lips Color: Pinkish (-) flaring of nares Lips Color: Pinkish Normal (-) lesions (-) lesions Normal (-) scars/ incisions (-) scars/ incisions Normal. (-) lumps (-) lumps Normal (-) mass (-) mass Normal Tongue: Color: Pink – red Tongue: Color: Pink – red Normal (-) lesions (-) lesions (-) thrush (-) thrush Gums: Gums: Color: Pink – Color: Pink – Symmetry Normal Normal Normal Normal 18 | P a g e .

Neck Inspection Red Red Oral Mucosa: Color: Pinkish (+) Moisture Oral Mucosa: Color: Pinkish (+) Moisture (-) lesions (-) lesions (-) odor (-) odor Symmetricall y aligned Symmetricall y aligned Normal (-) scars (-) scars Normal (-) mass (-) mass Normal (-) swelling (-) swelling Normal (+) symmetrical expansion with respiration (+) symmetrical expansion with respiration Normal (-) retraction (-) retraction Normal (+) smooth (+) smooth Normal (+) warm (+) warm Normal (+) dry (+) dry Normal Normal Normal Normal Palpation Respiratory System Chest /Thorax/ Lungs Inspection Palpation Auscultatio n Heart 19 | P a g e Inspection Normal Normal (+) normal breath sounds (+) normal breath sounds (-) adventitious sound (-) visible PMI (-) adventitious sound (-) visible PMI Normal Normal .

and dorsalis pedis pulses Palpation Inspection Palpation 20 | P a g e Normal .Extremities Auscultatio n Inspection (+) regular rhythm (+) regular rhythm Normal (-) thrills (-) thrills Normal (-) murmurs (-)murmurs Normal Upper Extremities (-) pallor Upper Extremities (-) pallor Normal (-) rashes (-) rashes Normal (-) bruise (-) bruise Normal (-) swelling (-) swelling Normal (-) edema (-) edema Normal (-) contraption (-) Contraption Normal (+) Radial and Brachial Pulses (+) Radial and Brachial Pulses Lower Extremities Lower Extremities Normal (-) pallor (-) pallor Normal (-) rashes (-) rashes Normal (-) bruise (-) bruise Normal (-) swelling (-) swelling Normal (-) edema (-) edema Normal (+) popliteal. and dorsalis pedis pulses (+) popliteal. posterior tibial. posterior tibial.

Abdomen Genitalia 21 | P a g e Inspection Inspection Symmetrical Symmetrical Normal (+) globular shape (+) globular shape Normal (-) masses (-) masses Normal (-) lesions (-) lesions Normal (-) discharges (-) discharges Normal .

2014 6AM-2PM IX. LVI. XXX. oral and body hygiene. February 3. XLIX.VII. XXIII. XXXVII. CBG monitoring XXV. XVII. XX. LIV. LII. XXVIII. -Client understands the importance of the order. LVIII. XXVI. XXXIX. PT REACTION/ EVALUATION XLVIII. L. LIII. LVII. DOCTOR’S ORDER Continuous present management XVI. XVIII. XLIII. XLI. XLII. LV. -Instruct patient not to manipulate affected and to avoid infection. 22 | P a g e X. XXIV. LIX. LI. XIII. -Client understands the importance of taking of CBG before meals. -Instruct patient to have CBG monitoring first before taking meals. -Instruct patient to perform hand. XL. XXXVIII. -Client was monitored and checked thoroughly. XXXII. XXI. DATE & SHIFT XII. XXXI. XIV. XI. XXVII. XXII. Course in the Ward VIII. -Monitor vital signs and perform bedside care. XIX. Continue giving medications XXIX. -Client received medication . XV. NURSING RESPONSIBILI TIES XXXVI.

-Monitor vital signs and perform bedside care. -Client was monitored and checked thoroughly. XCV. XCVII. Refer accordingly XXXIV. Continue giving medications LXXIII. -Client understands the importance of the order. XCIII. XC. LXV. LXIII. LXXX. LXXI. -Instruct patient not to manipulate accordingly. XXXV. oral and body hygiene. -Administer medications with the right dosage. route and frequency. LXVI. XCIV. 2014 6AM-2PM 23 | P a g e LXII. LXX. LXI. XLIV. LXXIX. XLVI. February 4. LXXII. LX. . XLV.XXXIII. and without adding injury to the patient. LXVIII. XCI. LXVII. LXXXIV. -Instruct patient to perform hand. XLVII. LXXXIX. XCVI. LXXXII. Continuous present management LXIV. LXIX. -Refer to the physician if there is any alterations. XCII. LXXXIII. LXXXI.

Refer accordingly LXXVIII. LXXXVIII. 24 | P a g e affected and to avoid infection. LXXV. -Refer to the physician if there is any alterations. LXXVII. route and frequency. -Client received medication accordingly. LXXVI. . CIII. CIV. CI. CV. LXXXVII. XCIX. LXXXVI. C. -Administer medications with the right dosage. XCVIII.LXXIV. CII. and without adding injury to the patient. LXXXV.

indicate s iron deficien cy CXX.06. may indicate anaemi a or fatigue CXXIV. decreas e. CXXXII. 0.5 CXVII.03 CXXXVI. Diagnostics CVII.400. COMPO NENTS CX. 0.39 CXIX. 4-11 x10^9/l CXXVI.04 CXXI. INTERP RETATI ON CXVI.4 CXXXI. CXXXV.2 CXXVII. 0. DIFFE RENTIAL COUNT CXXXIV. ormal n . 4. HEMATOLOGY: January 18 2014 CIX.11. norm al CXXVIII. 14-18 g/L CXIII. 0.020.0 CXXIII. may indicate risk for anaemi a CXXIX. 5. Hemogl obin CXIV.54 CXXII. E osinophi ls Neutrop 25 | P a g e CXII.CVI. Decreas e. Red Blood Cells Count CXXX. 12. decre ase. CXXXIII. RESULT CXI. CVIII. White Blood Cells Count CXXV. NORMA L VALUE CXV.Hemato crit CXVIII. CXXXVII.

incre ase. 0.8 CLXXIV. 0. 14-18 g/L CLXVIII.33 CLXX.hil CXXXVIII. JANUARY 22 2014 CLX. ESR CXXXIX. 0.0. INTE RPRET ATION CLXVII. 0-15 mm/hr CXLI. Platelet s Count CLIV. Hemo globin CLXI.63 CXLIII. S egment ers CXLII. Decre ased .05 CLII. 8. increas e in inflamm ation CLVIII.5 CLXII. 0. normal CLVII. White Blood CLXXIII. Mono cytes CL.06 CLI.020. decre ase. 81 CXL. RESULT CLXV.40 CXLVIII. may indicate iron deficien cy CLXXI. Lympho cyctes CXLVI. 0. may indicate inflamm ation CLIII.200. decre ase. 4-11 x10^9/l 26 | P a g e CLXIII. COMPO NENTS CLXIV.70 CXLIV. CLIX.28 CXLVII. Hema tocrit CLXIX. may indicate anemia or fatigue CLXXV.400. 0. normal CXLV. 150-450 x10^9/L CLVI.500. 10. normal CXLIX.54 CLXXII. 360 CLV. 0. NOR MAL VALUE CLXVI.

radiatio n therapy. S egment ers CXCII.200.40 CXCVIII. ESR 27 | P a g e 3 . R CLXXVII. ed Blood Cells Count CLXXX. 0 .05 CCII. result of chemot herapy. decre ase. CLXXXVI.06 CCI. CLXXIX. or immune system disorder s.Cells Count CLXXVI.70 CXCIV.4 CXC. ormal CLXXVIII.Lympho cyctes CXCVI. 0. normal CXCV.500. may indicate risk for anemia CLXXXIII. 315 CCV. CLXXXV. 0.04 CLXXXVII. 0-15 CXCI. normal CXCIX. 0. leucope nia. 65 0 CLXXXII.0. 0. Platelet s Count CCIV.31 CXCVII. E osinophi ls Neutrop hil CLXXXVIII. 0.0-6. 150-450 x10^9/L CCVI. d ecrease. normal CCVII.5 CLXXXI.03 CLXXXIX. DIFFE RENTIAL COUNT CLXXXIV. Mono cytes CC.02-0. . 5 . may indicate risk for anemia CCIII.60 CXCIII.increas n .020.

0 . 0. 5.February 23. COMPO NENTS CCXI. 0. decre ase.Segmen 28 | P a g e CCXX. R ed Blood Cells Count CCXXXII. norm al CCXXXIV. Hemo globin CCXV. CCXXX.02-0. INTE RPRET ATION CCXVII.mm/hr e in inflamm ation CCVIII.RESULT CCXIV. CCXXXVII.03 CCXLI.12. NOR MAL VALUE CCXVI.1 4 CCXXXIII. CCXII. 2014 CCX. E osinophi ls Neutrop hil CCXL.06. 0. Hema tocrit CCXXIII. 4-11 x10^9/l CCXXIV. 14-18 g/L 0. decre ase.400.4 CCXIII.0 CCXIX. 11 CCXXVIII. . norm al CCXXVI. may indicate risk for anemia CCXXXI. .04 CCXXXIX. D IFFEREN TIAL COUNT CCXXXVI.62 0 CCXXIX.50- CCXLIII.54 CCXXV.37 CCXXI. CCXXII. may indicate risk for anemia CCXVIII. W hite Blood Cells Count CCXXVII. norm n . CCIX. ormal CCXLII. CCXXXV. CCXXXVIII.

40-0. 0. 0.norm al CCL.54 CCLXV.020. d ecrease. 355 0.6 CCLXXI. INTE RPRET ATION CCLXIX. 2014 CCLXII. d ecrease. 0. 0. in blood disorder s.10 CCLIII. 0 . may indicate risk for anemia CCLXXIII. 1 1. normal CCLIV. ESR CCXLV. may indicate anemia or . CCLXI. norm al CCLX. 0. Lymp hocycte s CCXLVIII. Platelet s Count CCLVI.200.40 al CCXLVII. 0-15 mm/hr CCLVII. Hemo globin CCLXX. 0. in autoim mune disorder s.ters CCXLIV. February 26.70 CCXLVI. M onocyte s CCLII.36 CCLXIV. 150450 x10^9/L CCLVIII. R ESULT CCLXVII.05 CCLI. Increase respons e to chronic infectio ns.25 CCXLIX. 1 4-18 g/L CCLXXII.7 CCLIX. CCLV. COM PONEN TS CCLXVI. Hema tocrit 29 | P a g e CCLXIII. N ORMAL VALUE CCLXVIII.

Platel ets Count CCCVII. 0.05 CCCIII. Mono cytes CCXCII.CCLXXV. 30 | P a g e CCXCVI.02-0. 0.4 . CCLXXXIII. may indicate risk for anemia CCLXXXVI. 0. Incre ase. CCCVI. norm al CCXCVIII. CCCIV. R ed Blood Cells Count CCLXXVI.07 CCCI. CCXC. 345 CCCV.8 CCLXXX.500. . infectio n or inflamm ation CCXCIV.0-6. Lymp hocycte s CCXCIX.06 CCLXXXV. 0 CCLXXXIX.26 February 03.150-450 x10^9/L CCCVIII. 2014 CCXCIII. . n ormal CCLXXXII. body is fighting off somethi ng viral.020. W hite Blood Cells Count CCLXXIX. 0.0 CCLXXXVIII. D IFFEREN TIAL COUNT CCLXXXVII. E osinophi ls Neutrop hil CCLXXXIV. Segm enters CCXCV. 0.70 CCXCVII. Incre ase. 0 . n ormal CCCII. 4 -11 x10^9/l 4 CCLXXXI.61 CCC. 5 . d ecrease.04 CCXCI.40 fatigue CCLXXIV. 8 CCLXXVII. CCLXXVIII. norm al . 0 .20-0.

CCCIX. . may indicate risk for anemia CCCXX. CCCXXXVIII. CCCXXXIX.18 CCCXXXIII. d ecrease. 4 -11 x10^9/l 3 CCCXXVIII. W hite Blood Cells Count CCCXXVI. 0 .34 0 CCCXIX. . I ncrease infectio n or inflamm ation CCCXLII.04 CCCXLI.40 CCCXII. 1 CCCXXIV. CCCXXXIV. RESU LT CCCXVII. Hemo globin CCCX. n ormal CCCXXIX. 0 CCCXXXVII. . COM PONEN TS CCCXIII. D IFFEREN TIAL COUNT CCCXXXV. CCCXXV. . d ecrease.1 1 CCCXXVII.4 CCCXXXI. 5 . d ecrease.7 CCCXXXVI. 0. may indicate anemia or fatigue CCCXXI. 0. may indicate risk for anemia CCCXXX. 11. E osinophi ls Neutrop hil CCCXXXII. 0.400.INTE RPRET ATION CCCXVI. R ed Blood Cells Count CCCXXIII. H ematocr it CCCXVIII. L ymphoc 31 | P a g e CCCXI. 14-18 g/L CCCXIV.0-6.200.02-0.54 CCCXXII.05 CCCXL. NOR MAL VALUE CCCXV. decre ase.

CCCLXXVI.02-0. CCCLXXXIX. CCCLXXV.CCCLXVI. CCCXCIX. 58 CCCXLVI. body is fighting off somethi ng viral. M onocyte s CCCXLVIII.07 CCCXLIX.CCCLXXXIII.0. Gluc 7.0. 2. CCCLXIV. CCCXCVI. CCCLXXVIII.5 M norm 1 45. CCCLXXXV. norm al CCCLV.ytes CCCXLIV. CCCLXXXVIII. 0 .CCCXCV. CCCLXV. CCCXCIII. CCCLXXI.4 U/ Incre 20 0U or ma l CCCXCI. CCCLXX. CCCLXVII. CCCXLV. in inflamm ation CCCLIX.50-0. norm al CCCLXIII. ESR CCCLVI. January 18 CCCLXII. CCCLXXVII.CCCXCIV. CCCXCVIII. CCCXCVII. 0-15 mm/hr CCCLVII. Incre ase. CCCLI. CCCLXXXVI. P latelet Count CCCLII. CCCLXIX. CCCLXXXIV. CCCLXXIV. Panel11 CCCLXXXII. m normal CCCLXXXI. TES R NO U INTE R N U INTERP RE TA TI ON CCCLXXII. CCCLXXX. CCCXLVII.150-450 x10^9/L CCCLIII.70 CCCLVIII. CCCLXVIII. Segm ent CCCLX. CCCLXXIII. n SGO 2 0. CCCLXXIX. 0 . I ncrease . CCCXCII. 32 | P a g e .05 3 CCCL. CHEMISTRY SECTION may indicate infectio n CCCXLIII.70 CCCLXI. CCCXC. 86 CCCLIV.CCCLXXXVII.

. CDXVI. URE CDXX. CDIX.5 CDXIII. CRE 1 45. CDXXXI. CDXXVII. 3. 13 CDIV. kid ne ys ma y not wo rki ng pro per ly. POT CDXI. 13 CDX. m or ma l CDXXIV. CDXXIII. 3.CDXXX. CDII. M norm CDXIX. CDXXIX. m Increase.CDXXXII.1 CDXXII. n 4. CDXIV. U Incre CDXXXVII. Panel 7 CDI. CDXVII. 8. 33 | P a g e U normal CDVIII. 0. CDXII. CDXXV. 13 CDVII. 2. kid ne ys ma y not wo rki ng pro per ly. nor m ma l CDXV. m Decrease . M CDV. CDXXXIII.4 U/ Incre 20 0- CDIII. 1. CDXXXVI.SGP 2 CD.CDXVIII. M Incre CDXXVIII. SODI 1 0. CDXXXIV. CDXXI. CDXXVI. norm CDVI. 4. 22 6. CDXXXV.

CDLXII.51 CDXLVII.CDLVIII. January 23. M no 1 6. CDXLII. CDLXXXII. kidn eys ma y are not wor king pro perl y CDLXVIII. CDLXXXVII. M Increase. CDXLV. CDLXXXVIII. CDLIII. CDLII. CDLXXIV. CDLXI. CDLXXVI. Test January 22.1 M In 10 74. CDLXXXIV. CDLVI. CDLI.CDXXXVIII. 201 CDLXX.CDLXXXIII. URE 5 2. CDLXXIII.CDLXXXVI. CDLXXVIII.CDXLVI. M Increase . 34 | P a g e . CDLXXXI. CDLXXII. CDLXVII. CDXLVIII. U INTERPR ETA TIO N CDLVII. 2014 CDXLI. CDLIV. 1 45 U Inc 1 0. CDLXXV. CDLXXIX. 4. CRE CDLX.CDXLIV. BUN/CREA CDL. CDXXXIX. CDLXXXV. CDLXXVII. CDLXIV. CDLXV. R NO U IN R NOR CDXLIX. CDXLIII. n M orm al CDLXVI.CHEMISTRY SECTION CDLXXI.0CDLIX. CDLV. CDLXIII. CDLXIX. CDXL. Fasti 6. TES R NO UN IN RE NO U INTERP R ET AT IO N CDLXXX.

CDXCIII. SMEAR SHOWS FEW EPITHELIAL CELLS AND LEUKOCYTES. Microscopic Examination: DV. CDXC. CDXCVIII. GRAM STAIN DIII. 2014 D. CDXCIV. CDXCVII. January 18. NO MICROORGANISM SEEN. CDXCIX.in di ca te s hy pe rgl yc e mi a CDLXXXIX. CDXCV. CDXCII. CDXCVI. Microbiology Examination: DII. 35 | P a g e KOH . DI. Specimen: Ocular Discharge DIV. CDXCI.

DXIII. Mediot tinum and visualized osseous structures are unremarkable. Examination: Chest DXI. 2014 DX. DXVI. Follow-up examination to 1/10/14 shows no significant change in the fibriotic densities in both upper lobes which may be from previous koch’s infection. Other findings remain unchanged. KOH-NEGATIVE DVII. DXVIII. Film number: 14-00733 DXII. DXX. X-RAY DIX.DVI. DXXI. The heart is not enlarge. 36 | P a g e Anatomy and Physiology . DXIX. DXVII. DXXII. January 18. DXIV. DXV. DVIII.

The experience of sight is the result of very highlevel processing of the basic electrical impulses which are the raw input from the eyes themselves.DXXIII. The optic nerves join together in the brain in such a way that images from both eyes are merged to give binocular vision. From the visual cortex. DXXVII. DXXVIII. DXXV. a nerve which connects the back of the eye to the brain. The part of the brain which receives these visual messages is called the visual cortex and lies at the very back of the brain. DXXXII. DXXX. DXXVI. Important tissues of the eye 37 | P a g e . DXXXI. DXXIX. gather and focus light from the object and transmit a clear image to the light-sensitive tissues which line the back of the eye where the image is received and initially processed. connections reach out to many other parts of the brain. The eye is the organ of sight. The image is then transmitted by electrical impulses along the optic nerve. DXXXIV. DXXIV.5cm diameter. It is a small paired organ. The function of the eye is to target an object of interest. each eye being a leathery sphere of about 2. DXXXIII.

It consists of very finely layered and delicate nerve tissue. firm jelly which forms the main bulk of the eye and helps to support its internal structure. It also acts as a powerful lens to refract or focus the light from an object. DXXXIX. Cornea: This is the clear front ‘window' of the eye.DXXXV. where its dense leathery wall is specialised to make it perfectly clear and allow clear images to enter the inside of the eye. It is also a gland which produces a watery fluid. The central part of the retina is the part we use when we look at 38 | P a g e . DXXXVII. ciliary body. iris and cornea.Lens: This is a clear specialised protein structure which helps focus the images and adjusts the eye's focusing power according to whether the object being viewed is close or far away. Iris: Acts as a diaphragm or circular shutter to control the amount of light entering the eye. DXXXVI. DXLII.Retina: This is the nerve tissue which lines the inside of the eye. DXLI. DXL. angle. The iris gives the eye its beautiful colour. the aqueous fluid. E ye anterior chamber cross-section with lens. DXXXVIII. Vitreous Gel: This is a clear. Ciliary Body: This is a muscle which changes the shape of the lens to allow clear fine focusing. The balance between the production and the drainage of the aqueous is what determines the pressure to which the eye is ‘pumped up'.

they are gathered into a bundle which exits the eye through a fine grid of tiny holes in the wall of the eye and then extends back. Where they all meet. impulses to the brain.something. taking the DXLIV. It contains the greatest concentration of light-sensitive cells. DXLIII. DXLV. like a fine cable. This part of the retina is called the macula. There are good reflex mechanisms to protect the eye and a good system of washing (with tears) and wiping the clear front surface (the eyelids' blinking action). 39 | P a g e . All of these tissues are finely structured and most of them are quite delicate except for the outer wall of the eye which is quite tough. Optic Nerve: This structure is formed from all the fine nerve fibres which come from all over the retina. so the eye sits in a wellprotected cavity in the face (called the orbit) where it is surrounded by bone which is rigid in parts and able to crumple in other parts. DXLVI. Common problems DXLVII. called photoreceptors. The other tissues need protection.

All of these conditions can and do cause blindness. There are various common ways for the pressure to become abnormally high. https://youtube. DLI. the macula. Optic Nerve: If the pressure within an eye is too high. Trauma is an important cause of vision loss in impoverished agricultural communities. by infections such as trachoma. Macular degeneration is the main cause of untreatable visual loss in developed countries and is very difficult to treat. Retina: Can be affected by many diseases. DL. The main ones are an ageing change in the central part. Trachoma and nutritional blindness are major sight-affecting problems in developing parts of the world where many people live in poverty. DLV. Cornea: Can be affected by trauma. DLIII. 40 | P a g e .DXLVIII. People's susceptibility to this damage is highly variable. Lens: When the lens loses its clarity light transmission is affected severely because all light entering the eye is focused there. DLIV. DLII.googleapis. and by nutritional problems such as Vitamin A deficiency (called Nutritional Blindness) which leads to gross abnormalities and dryness of the surface cells.com/v/sQRwViF0EBw%26hl=en DLVI. DLVIII. It is the major cause of blindness in the world today. DXLIX. Glaucoma is a major cause of blindness and visual disability throughout the world. Cataract is not preventable but it is treatable. Macula with normal eyeball anatomy. as diabetes becomes more common. called diabetic retinopathy. called macular degeneration. This loss of clarity is called cataract. This condition is called glaucoma. DLVII. it can damage the optic nerve at the point where it leaves the eye. and the effects of diabetes on the retina. It is becoming a rapidly increasing problem worldwide. Diabetic retinopathy can be treated with laser but it must be identified early before it becomes too advanced to treat.

DLX. Headac he DCIII. Sign s and Sympt oms DLXXII. Endopt halmiti s DLXXIV. DLXXXIX.Sensitivi ty to light DXCIX. DLXII. DXCIV. R ed eyes DXCI. DLXIX. DLXXXVIII. Cornea l Lacera tion DLXXIX. DXC. DLXXVI. DLXV. x DXCVII. DLXVIII.DLIX. DLXXX. DCI. x DLXXXVI. Differential Diagnosis DLXX. P ain DLXXXVII. DLXVII. DCII. DLXXIII. DLXXVII. DLXXXII. Ulcerat ive Keratiti s DLXXVIII. DLXVI. DLXXXI. DLXIII. Loss of vision DLXXXIII. DLXXXV. Swollen Eyelids DXCV. DXCII. DLXXXIV. DLXXV. DC. 41 | P a g e x DXCVIII. DXCIII. DXCVI. DLXXI. DLXI. DLXIV. x .

DCXVI. DCIX. DCXVIII. DCVII. DCXVII. DCX. DCVI. DCXIII. DCXV. DCXIV.DCIV. DCV. 42 | P a g e . DCVIII. DCXI. DCXII.

DCXIX. Drug Study
DCXX. D
ru
g
N
a
m
e

43 | P a g e

DCXXI. C
las
sifi
cat
ion

DCXXII.
Action

DCXXIII.
Indication

DCXXIV.
Dosage/
Rout
e/
DCXXV.Fr
equ
ency

DCXXVI.
Nu
rsing
Considera
tions

DCXXVII
Evaluati
n

DCXXVIII.
DCXXIX.
Generic
na
m
e:
DCXXX.
DCXXXI.
Timolol
m
al
ea
te
DCXXXII.
DCXXXIII.
Brand
N
a
m
e:
DCXXXIV.
betimol
DCXXXV.

DCXXXVI.
DCXXXVII.
Pharmac
olo
gic
:
DCXXXVIII.
BetaAdr
ene
rgic
Blo
cke
r
DCXXXIX.
Therape
uti
c:
DCXL. A
ntihyp
ert
ens
ive
DCXLI.

44 | P a g e

DCXLIV.
DCXLV. Bl
ocks
stim
ulati
on of
beta
1adre
nergi
c
and
beta
2adre
nergi
c
rece
ptor
sites
DCXLVI.
DCXLVII.
DCXLVIII.
Reduce
aque
ous
prod
uctio
n
DCXLIX.
DCL.
DCLI. Decr

DCLII.
DCLIII. Ocula
r
hyperte
nsion
and
open
angle
glauco
ma

DCLIV.
DCLV. 1gtts
To
OS
BID

DCLVI.
DCLVII. -give
ophthalmic
drugs
atleast 10
minutes
before
giving gel
form of
drug
DCLVIII.
DCLIX. -monitor
diabetic
patients
systemic
beta
blocking
effects can
mask some
signs and
symptoms
of
hypoglyce
mia
DCLX.
DCLXI. -some
patients
may need a
few weeks
of
treatment
to stabilize
pressure

DCLXIV.
DCLXV. T
e
intr
ocu
ar
pre
sur
was
red
ced

DCXLII.
DCXLIII.

ease
intra
ocul
ar
pres
sure

lowerimg
response
DCLXII.
DCLXIII. -drug can
be used
safely in
patients
with
glaucoma

DCLXVI.
DCLXVII.
DCLXVIII.
Drug
Na
me
45 | P a g e

DCLXIX.
Classific
ati
on

DCLXX.Act
ion

DCLXXI.
Indication

DCLXXII.
Dosage/
Rou
te/

DCLXXIV.
Nu
rsing
Considera
tions

DCLXXV.
Evaluatio
n

26 units prebrea kfast DCCXVI. sever e diabe tic ketoa cidos is DCCIX. DCCXIII. Pharma col ogi c: DCLXXXIV. Sti mulat es carbo hydrat e metab olism DCXCII. DCLXXXVIII. DCCVII. DCCXVIII.DCLXXVI. DCCXXVIII. DCXC. DCXCIV. -don’t use insulin that changes color or becomes clumped in appearanc e DCCXXI. Frequenc y DCCXIV. regula insulin is for patients with circulatory collapse and diabetic ketoacidosi s DCCXIX. ch eck expiration date on vial before using contents DCCXXVII. Pancreati c Hor mo ne DCLXXXV. DCCXV. Brand Na me : DCLXXXI. hype rkale mia DCCXII. Hypoglyc em ic DCLXXXVII. DCLXXXIII.16 units predinn er DCCXVII. Generic na me : DCLXXVIII. Insulin HN DCLXXIX. DCLXXVII. Increase glucos e transp ort DCLXXXIX. contr ol of hype rglyc emia DCCXI. DCXCI. The gluc ose will decr ease and main taine d . DCCVIII. DCXCIII. DCCXX. Therape uti c: DCLXXXVI. mild diabe tic ketoa cidos is DCCX. Pro motes phosp horyla tion of glucos e in lver DCXCV. DCLXXX. DCLXXIII. DCCXXII. Humulin 50/ 50 46 | P a g e DCLXXXII.

Inhi bits releas e of fatty acids DCCIV. DCCXXIV. Affects fat and protei n metab olism DCXCVIII. DCC. DCCIII. DCCV. DCCII. DCXCVII. monitor patients for hyperglyce mia DCCXXV.DCXCVI. DCXCIX. Stimul ates protei n synth esis DCCI. DCCXXVI. Dec reases phosp hate and potas 47 | P a g e DCCXXIII. DCCVI. some patients may develop insulin resistance and need large insulin doses to control symptoms of diabetes .

DCCXXXI. Drug Name DCCXXXII. DCCXXX. DCCXXXIII. Eva luatio n 48 | P a g e . DCCXXXVII. DCCXXXV. Dosage/Ro ute/Fr eque ncy DCCXXXVIII.sium DCCXXIX. Classificati on DCCXXXIV. Action/Indi catio n DCCXXXVI. Nursing Consi derati ons DCCXL. DCCXXXIX.

DCCLXXIX. Generic Nam e: DCCXLIII. DCCLXIX. DCCLV. Th erap euti c: DCCLIII. DCCXLII. DCCLXXV. Brand Nam e: DCCXLVI. moxifloxaci n DCCXLIV. Administer the drug at the same time everyday DCCLXX. An tiinfec tive DCCLIV. DCCLXXIII. DCCLXXI. 49 | P a g e DCCLVI. DCCXLV. -Your vision may be temporarily blurred or unstable after applying this DCCLXXVIII. Actio n: DCCLX. Avelox DCCXLVII. DCCLIX. Pharmaco logic : DCCL. -When using the eyedrops be careful not to let the tip of the bottle touch your eyes because bacteria may get into the eye drops DCCLXXIV. -To treat bacteri al conjun ctivitis DCCLVIII.DCCXLI. DCCLII. Patient’s ba ct eri al co nj un cti vit is wa s tre at ed . DCCXLVIII. DCCLXVII. -Use the drug until you finish the prescription and the full course of the drug therapy DCCLXXII. Inhib its synthe sis of bacteri al enzym e DNA gyrase by counte racting excessi ve superc oiling of DNA during replicat ion or transcr DCCLXVI. Indic ation: DCCLVII. DCCXLIX. Av elox DCCLI. E/D 1gtt to O D TI D DCCLXVIII.

use machinery. DCCLXXXIX. DCCXC. Action/Indi catio n DCCLXXXVII. DCCLXXVI.Nursing Dosage/ Considera Ro tions ut e/ Fr eq DCCXCI. Drug Nam e 50 | P a g e DCCLXXXIII. DCCLXIII.Use of this medication for prolonged or repeated periods may result in a secondary infection. DCCLXXXVIII. or do any activity that requires clear vision until you are sure you can perform such activities safely. DCCLXII. Evaluation .iption DCCLXI. DCCLXIV. DCCLXXX. drug. Inhibiting DNA gyrase causes rapid and slowgrowin g bacteri al cells to die DCCLXV. DCCLXXXIV. DCCXCII. DCCLXXVII. -Do not drive. DCCLXXXI. Classificati on DCCLXXXVI. DCCLXXXV. DCCLXXXII.

It cataly zes the revers ible reacti on involvi ng the hydra tion of carbo n dioxid e and the dehyd ue nc y DCCCXVI. Dorzolamid e optha lmic DCCXCVI. DCCCXXX. Frequenc y: DCCCXXIV. DCCXCVII. Patient’s intrao cular press ure was decre ased DCCCXXVII. DCCCXVII. they should discontinue use and seek their physician’s advice. Ph arma colog ic: DCCCII. Acti on: DCCCXI. Therapeuti c: DCCCV. DCCCVII. Route: DCCCXXI. DCCXCIV. Patients should be instructed to avoid allowing . 51 | P a g e DCCC. Patients should be advised that if they develop any ocular reactions. OD DCCCXXII. DCCCX. Dosage: DCCCXVIII. TID DCCCXXV. particularly conjunctivit is and lid reactions. DCCCXXXI. DCCCIV. 1 drops DCCCXIX. Anti glauc oma agent DCCCVI. Generic Nam e: DCCXCV. Brand Nam e: DCCXCVIII. DCCCI. DCCCXXVI. DCCCXX. Indication: DCCCVIII.DCCXCIII. -To reduce intrao cular press ure DCCCIX. Bet aadren ergic block er DCCCIII. DCCCXXIII. Trusopt DCCXCIX.

if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures. Patients should also be instructed that ocular solutions. Inhibition of carbo nic anhyd rase in the ciliary proce sses of the eye decre ases aqueo us humor secret ion. DCCCXXVIII.ration of carbo nic acid. presu mably by slowin g the forma tion of 52 | P a g e the tip of the dispensing container to contact the eye or surrounding structures. ↓ DCCCXIII. can become contaminat . DCCCXII.

DCCCXIV. -If more than one topical ophthalmic drug is being used. Serious damage to the eye and subsequent loss of vision may result from using contaminat ed solutions. DCCCXXIX. ↓ DCCCXV.bicarb onate ions with subse quent reduct ion in sodiu m and fluid transp ort. the drugs should be administere d at least ten minutes . The result is a reduct ion in intrao cular press ure (IOP) 53 | P a g e ed by common bacteria known to cause ocular infections.

DCCCXXXII.apart. DCCCXXXIII. 54 | P a g e .

DCCCLIII. DCCCXLIII. DCCCXXXVII. Nu Dosage/ rsing Rout Considera e/ tions DCCCXXXIX. DCCCLV. DCCCLXX. -subclinical scurvy DCCCLXII.DCCCXXXIV. severe febrile or chronic disease states DCCCLXIV. delayed fracture or wound healing. sti mu lat es col lag en for ma tio n an d tis su e rep air Asc orb ic aci d DCCCXLV. Frequenc y DCCCLXIX. DCCCLVI. DCCCXLI Evaluati n DCCCLXX DCCCLXX -vitamin C defi ien was pre ent d. Drug Classifica Na tion me DCCCXXXVI. DCCCXL. Brand Na me : DCCCXLVIII. DCCCLIV. Action Indication DCCCXLII. -to prevent vitamin DCCCXXXVIII. cecon DCCCXLIX. Vi tami ns and min eral s DCCCLII. when giving 500mg/tab for urine OD acidification . take large of vitamin c in divided amounts because the body uses only what is needed at a particular time excretes the rest in urine DCCCLXXV. DCCCXLVI. DCCCXLVII. DCCCLXX . DCCCLXXI. DCCCLIX. DCCCLXXIV. -extensives burns. DCCCLI. check urine ph to ensure efficacy DCCCLXXIII. Generic na me : DCCCXLIV. DCCCLXIII. DCCCLVII. DCCCL. DCCCLVIII. DCCCXXXV. DCCCLXI. DCCCLXXII. 55 | P a g e DCCCLX. DCCCLXV.

DCCCLXXXIV. DCCCLXXXII.c deficien cy DCCCLXVI.DCCCXC. . DCCCLXXXIII. DCCCLXXXV. DCCCLXXXI.DCCCLXXXVI. 56 | P a g e DCCCLXXXVII. Nu DCCCXCI. DCCCLXVII. DCCCLXXVI. to acidify urine DCCCLXVIII. DCCCLXXXVIII. megadoses can interfere with absorption of vitamin B12 DCCCLXXVII.

DCCCXCIII. CMXVIII. mcg determine OD reticulocyte count. Cyanocoba lami n DCCCXCV. CM. hematocrit. CMII. Red blood cell forma tion CMVII. Frequenc y CMXIII. CMXV.-it impr oves dieta ry defic ienc y and incre ased activ ation of neur ons . DCCCXCVI. CMXXIII.Drug Nam e DCCCXCII. Brand Nam e: DCCCXCVII. perni cious anem ia or vita min B12 mala bsorp tion CMXI.. CMIV. CMXX. vita min B12 defici ency from inade quat e diet CMIX. CMV. CMXVII. CMXIV. Activa tion of folic acid coenz ymes CMIII. vitamin B12. CMXII. 10 CMXVI. CMVI. CMVIII. -don’t mix parenteral preparation s in same syringe with other drugs Evaluatio n CMXXII. Dosage/ rsing Rou Considera te/ tions DCCCLXXXIX. nascobal DCCCXCVIII. Vi ta m in s a n d m in er al s Action Indication CMI. iron. and folate levels. CMX. 57 | P a g e Classifi c a ti o n DCCCXCIX. Generic nam e: DCCCXCIV.obtain a sensitivity test history before administrat ion CMXIX.

Evaluatio . CMXXVII. Action CMXXX. Drug 58 | P a g e CMXXVIII. Nu rsing CMXXXIV. Classific CMXXIX. CMXXV.CMXXI. Indicatio CMXXXI. CMXXIV. CMXXVI. Dosage/ CMXXXIII.

preo pera tivel y to dimi nish ed secr etio ns and bloc k card iac vaga l Rou te/ CMXXXII. CMLV. CML. It enha ncin g cond uctio n thro ugh the AV node s and it may decr ease abso rptio n of antic holin ergic s . Brand N a m e: CMXL.N a m e CMXXXV. CMLVII. Pharma col ogi c: CMXLIV. Causi ng pupillar y dilation and accom modati CMLXI. 59 | P a g e ati on CMXLII. CMLXIV. Therape uti c: CMXLVIII. Block s choliner gic stimula tion to iris and ciliary bodies. S altr op in e CMXLI. A nti ch oli ner gic CMXLV. CMLXXVIII. Antiarrhy th mi cs CMXLIX. watch for tachycardia in cardiac patients n CMLXXVII. CMLX. Generic na m e: CMXXXVII. CMLXXIV. 1g tt TIV OD Considera tions CMLXXI. Atropin e su lfa te CMXXXVIII. CMLVI. CMXXXVI. CMLII. CMLVIII. CMLIX. CMXXXIX. CMLIV. Frequenc y CMLXIX. may adverse reaction such as dry mouth. CMLXII. n CMLI. CMXLVII. sym pto mati c brad ycar dia CMLXIII. Inhibi ts acetylc holine CMLIII. monitor fluid intake and urine output drug causes urine retention and urinary hesitancy CMLXXV. CMXLVI. and constipatio n vary with the dose CMLXXIII. CMLXX. CMLXXVI. CMXLIII. CMLXXII.

CMLXVIII. .adju nct treat men t of pept ic ulce r dise ase CMLXVII. CMLXVI.on of paralysi s. refle xes CMLXV. -pupillary dilat ion in acut e infla mm ator y cond ition s of iris and 60 | P a g e because it may lead to ventricular fibrillation.

Classific CMLXXXIV.uvea l tract CMLXXIX. Indication CMLXXXVI. Drug 61 | P a g e CMLXXXIII. CMLXXX. Action CMLXXXV. CMLXXXI. CMLXXXII. Nu rsing CMLXXXIX Evaluatio . Dosage/ CMLXXXVIII.

MXXV. MXXIII. CMXCIV. Amlodi pi ne CMXCIII. hype rtens ion MXIV. -advise patient to minimize GI upset by eating small. 10 mg/t ab OD Considera tions MXVIII. MXXII. Anti hyp erte nsiv e MII. Pharmac olo gic: CMXCIX. MXVII. MVII. Brand N a m e: CMXCV. chron ic stabl e angin a MX. 62 | P a g e ati on CMXCVII. Frequenc y MXVI. Decre asing myoc ardial contra ctility and oxyge n dema nd MVIII. MXXI. frequent n MXXIV. norvasc CMXCVI. Rou te/ CMLXXXVII. Inhibit s calciu m ion influx across cardia c and smoot h muscl e cells MIV.N a m e CMXC. CMXCI. MXI. -monitor blood pressure frequently during intiation of therapy MXX. varia nt angin a MXII. MIX. -notify prescriber if signs of heart failure occur such as swelling of hands feet or shortness of breath. MXIII. MV. The rap eut ic: MI. may incre ase drug level and indu ced vaso dilati on . G en er ic na m e: CMXCII.C alci um Cha nnel Bloc ker M. MXV. MVI. MIII. MXIX. CMXCVIII.

MXXVII. MXXXIII. Evaluatio n . D osa ge/ Rou te/ MXXXII. Classific atio n MXXIX. Nu rsing Considera tions MXXXIV. Act ion MXXX.servings of food and drink plenty of fluids. MXXVI. In dicat ion MXXXI. Drug Na m e 63 | P a g e MXXVIII.

Pro motin g osmot ic instab ility. ta zi di m e MXLI. respir atory tract infect ions. MLXII. . MLII. Decr ease infec tion. A ntiinfe ctiv e MXLVIII. MXXXVI. e/ d 1gtt to OD Q3 MLXIII. MLIV. MLVII. T hrid Gen erat ion Cep halo spor ins MXLV. T her ape utic : MXLVII. P har ma col ogi c: MXLIV. MXXXIX. bone and joint infect ions. -obtain specimen for culture and sensitivity test before giving first dose MLXVII. MLVI. MXLVI. MXLIX. -Skin infect ions. monitor patient for MLXX. ML. urina ry tract and gyne colog ical infect ions. intra bdom inal infect ions Frequenc y MLXI. MLXXI. MLXVI. -if large doses are given therapy is prolonged or patient is at high risk. 64 | P a g e MXLII. usuall y bacter icidal MLIX. MLX. Third gener ation cepha lospor in MLI. MXLIII. MLXVIII. MLVIII. MLXIV. MLIII. Generic na m e: MXXXVII. Ceftazi di m e MXXXVIII. Brand Na m e: MXL.MXXXV. Inhibit s cell wall synth esis MLV. -before administrat ion ask patient if he is allergic to penicillins or cephalospo rins MLXV.

MLXXIII. . 65 | P a g e .signs and symptoms of infection MLXIX. MLXXII. MLXXIV.

inclu ding vasc ular MCV. . Nu rsing Considera tions MLXXXII Evaluati n MCXXVIII. mana ge hypert ension MCXXIII. T m her MLXXXVI.MLXXV. ape MLXXXVII. • Instruct patient to MCXLIII. An po tago ta nist ss MXCIV. MLXXVI. to detect hyperkalem ia. Classifica tion MXCI. MLXXIX. 66 | P a g e MLXXVII. MCIII. MXCII. Generic na m e: MLXXXV. MCXXII. 50mg PO BID MCXXVII. sites in many tissu es. MCXLI. smoo th musc le and adren al MCXXI. MCXXIV. MCXLII. Anti Brand hype N rten a m sive e: MLXXXIX. MCXXXI. Frequenc y MCXXV. MCXXX. H per nsio is ma age MCXXIX. Drug N a m e MLXXXIII. Indication MCII. • Monitor blood pressure and renal function. iu MXCV. as appropriate . MLXXXIV. MCXXXII. • Periodically monitor patient’s serum potassium level. Action MLXXVIII. P har mac olog ic: Angi oten lo sin II sa rece rt ptor an MXCIII. MLXXXI. Block s bindi ng of angio tensi n II to recep tor MCIV. utic: MLXXXVIII. Dosage/ Rout e/ MLXXX. MCXXVI.

inh ibit effect s of MCXVIII. va soco nstric t MCIX. MCXVI. MCXXXV. nausea.an giote nsin avoid potassium containing MCXXXIII. MCXIII. MC. sec rete aldos teron e MCXV. MCVII. MCI. MCXI. MXCVIII. if he has prolonged diarrhea. MCVIII. MCXXXIV. MCXIV. MCX. or . • Advise patient to avoid exercising in hot MCXXXVI. MXC. stimu lates the adren al corte x MCXII. salt substitutes because that may increase risk of hyperkalem ia. of alcohol. instruct him to notify prescriber MCXXXVIII. 67 | P a g e gland s MCVI. MXCVII. we ather and drinking excessive amounts MCXXXVII. MCXVII.Cozaar MXCVI. MXCIX.

MCXX. MCXIX. Indication MCXLVIII. Action MCXLVII. Ev aluat ion . Drug Nam e 68 | P a g e MCXLV. MCXL. Frequency MCL. red uce blood press ure MCXLIV. Dosage/ Rout e/ MCXLIX.II MCXXXIX. vo miting. Nurs ing Cons idera tions MCLI. Cla ssific ation MCXLVI.

MCLXVI. Inhibits the enzy me DNA gyra se.) MCLXX. MCLXXXII. MCCI. MCLXIV. MCLXIII. Cipro MCLIX. MCLXXV. MCLXXI. MCLXXXVI. G en eri c na me : MCLIV. MCLXXXVIII. MCXCI.of bact erial DNA befo re it repli cate s. • Don’t give oral suspension by feeding MCLXXXV.MCLII. wh ich may lead to crystalluria and MCLXXXIX. . -To treat bone and joint infect ions caus ed MCLXXVIII. P har mac olog ic: Fluor oqui nolo ne MCLXII. MCLIII. MCLVI. MCLXXXIV. MCLXXXI. • Patient should be well hydrated during MCLXXXVII. MCLXI. MCXC. 69 | P a g e MCLX. the rapy to help prevent alkaline urine. MCLXVII. T her ape utic: Anti bioti c MCLXV. 500 mg caps ule TID MCLXXVII. Treat infec tion. tub e. c ipr of ox aci n MCLV. MCLXVIII. • Assess patient’s hepatic. MCLXXVI. by susc eptibl e orga nism s MCLXXIX.B ra nd Na me : MCLVIII. MCLXXX. MCLVII. ne phrotoxicity . MCCII. (res pons ible for the unwi ndin g and supe rcoili ng MCLXIX. MCLXXXIII.

If it occurs. ex pect to withhold drug and treat diarrhea. •Monitor patient closely for diarrhea. MCXCV. notify prescriber and MCXCVIII. if he’s receiving prolonged therapy. MCXCIII. MCXCIV.which may reflect pseudome mbranous MCXCVII. 70 | P a g e renal. causes bact erial cells to die MCLXXIII. and hematologi c MCXCII. as ordered. MCXCIX.MCLXXII. functions periodically . . MCLXXIV. MCXCVI. coli tis.

MCCIII. Dosage/ Rout e/ MCCVIII. Cla ssific ation MCCV. Ac tion MCCVI. Nu rsing Cons idera tions MCCX. Dr ug Nam e 71 | P a g e MCCIV. Frequency MCCIX.MCC. Ev aluat ion . In dicat ion MCCVII.

omepra zo le MCCXIV. 40 mg tab OD A. Brand N a m e MCCXVII. ne eded. • MCCLXVI.To prov ide shor tterm treat men t of MCCXXXIX. MCCL. MCCLIV. MCCXLI. macrocyt ic anemia. MCCXXVI. MCCXLII. MCCXXX. monitor patient for MCCLIII. active beni gn gast ric ulce r MCCXL. MCCXIX. also give an antacid. MCCXLIV. MCCXVI. . MCCXXXII. MCCXXXVII. MCCXXV. Pharmac olo gic: Sub stit ute d ben zimi daz ole MCCXXII. MCCXXI. in the morning for once-daily dosing. MCCLXVII. MCCXXXVIII. secretion MCCXXVIII. MCCXLVII. Increase gastric mucus and bicarb onate produc tion MCCXXXI. MCCXXIX. . MCCLI. MCCXXIII. Losec MCCXVIII. of vitamin B12.MCCXI. MCCXV. as prescribed. If MCCXLIX. Therape utic : Anti ulce r MCCXXIV. Creating protect ive 72 | P a g e MCCXLVI.C. • Give omeprazole before meals. Interferes with gastric acid MCCXXVII. Generic na m e: MCCXIII. • Because drug can interfere with absorption MCCLII. MCCXLIII. MCCXX. MCCLV. MCCXLV. MCCXII. -Gastric dise ases was prev ente d. preferably MCCXLVIII.

Easing discom fort from excess gastric acid MCCXXXV. MCCXXXIV. ibuprofen.• Advise patient to notify prescriber immediatel y MCCLXII. aspirin MCCLVI.prescripti on drug use. ab out abdominal . 73 | P a g e Encourage patient to avoid alcohol. and foods that may MCCLVII. MCCLX. products. MCCLVIII. MCCXXXVI. MCCLXI. inc rease gastric secretions during therapy. Tell him to notify all prescribers about MCCLIX.coatin g on gastric mucos a MCCXXXIII.

Drug Nam e 74 | P a g e MCCLXIX. MCCLXV. Classificat ion MCCLXX. Evaluation . MCCLXIV. Nursing Cons idera tions MCCLXXV. MCCLXIII. Action MCCLXXI. Frequency MCCLXXIV. Dosage/ Rout e/ MCCLXXIII.pain or diarrhea. Indication MCCLXXII. MCCLXVIII.

MCCXCI. MCCLXXXV. MCCXCIX. b inding sites on the 30S ribosom al MCCXCVI. MCCCXXII. wh ich may indicate pseudome mbranous MCCCXXXI MCCCXXXI -Bacteria was kille d. MCCLXXXVIII. 75 | P a g e MCCXC. R esults in bacterio static effects MCCC. B inds irreversi bly to one of two aminogl ycosideMCCXCV. Am tobram ino yc gly in cos su ide lfa MCCLXXXVI. MCCLXXVII.Inhibit s bacterial protein synthesi s MCCXCII. MCCXCIII. MCCCXI. MCCCXIX.MCCLXXVI. MCCCX. MCCCXIV. ele vated BUN and serum creatinine levels. te MCCLXXXVII. such as MCCCXVIII. To treat bac tere mia MCCCXII. •W atch for signs of nephrotoxi city. MCCCXVII. e/d OD 1gtt to OD MCCCXVI. MCCLXXIX. •M onitor patient closely for diarrhea. MCCXCIV. MCCLXXXIII. ne phrotoxicity . MCCXCVIII. s ubunit MCCXCVII. . Generic Pharma na col m ogi e: c: MCCLXXVIII. MCCCXV. • Expect dehydratio n to increase the risk of MCCCXXI. MCCCXX. MCCCXIII. MCCCXXIV. c Tobi MCCLXXXIX. MCCLXXXIV. MCCLXXX. MCCCXXIII. Therape Brand uti N c: a Ant m ibi e: oti MCCLXXXI. MCCLXXXII.

MCCCXXX.tobra mycin’s ability to accumul ate within MCCCIV. tha t’s severe or lasts longer than 3 days. MCCCVII. • Urge patient to immediatel y report highfreque ncy MCCCXXVIII. e xceeds the extracell ular level. MCCCIX. Remind patient that watery or bloody stools may . MCCCXXVII.MCCCI. Bacte ricidal effects may stem from MCCCIII. MCCCVI. • Urge patient to tell prescriber about diarrhea MCCCXXXI.cells MCCCV. 76 | P a g e MCCCXXV. coli tis caused by C. i ntracellu lar drug level MCCCVIII. he aring loss and vertigo MCCCXXIX. difficile. MCCCXXVI. MCCCII.

MCCCXL.occur 2 or more months after antibiotic therapy. Evaluation . tions Frequency MCCCXLI. MCCCXXXIV. Indication MCCCXXXVIII. Classificat ion MCCCXXXVI. Action MCCCXXXVII. Dosage/ Nursing Rout Cons e/ idera MCCCXXXIX. Drug Nam e 77 | P a g e MCCCXXXV.

MCCCLXXVI. Therape utic : Anti biot ic MCCCLVI. MCCCLXVIII. MCCCLXI. dru g level have occurred in such patients taking multiple oral doses of vancomyci n. E/D 1gtt to OD Q3 MCCCLX. MCCCLXIX. Inhibits bacter ial RNA and cell wall synth esis MCCCLIX. MCCCLXV. •M onitor serum vancomyci n concentrati on in patients with renal impairment or colitis because significant increases in blood MCCCLXXVII. Alters perme ability of bacter ial memb ranes MCCCLXIII. methicillinresist ant Stap hyloc occu s MCCCLXXI. MCCCL. MCCCLIII. MCCCLVII. MCCCLXXIX. vancom yc in MCCCXLV. MCCCLXXIII. MCCCLXII. MCCCLXXX . Brand N a m e: MCCCXLVIII. MCCCLXXIV. Pharmac olo gic: Tric ycli c glyc ope ptid e MCCCLIV. • Check CBC results and serum MCCCLXXX MCCCLXXX -Bacteria was kille d. MCCCLI. MCCCLXIV. MCCCLII. MCCCXLVII. Vancoci n MCCCXLIX.MCCCXLII. aureus MCCCLXXII. MCCCLVIII. MCCCLXXVIII. Generic na m e: MCCCXLIV. MCCCXLIII. hydroc hl or id e MCCCXLVI. -To treat bacte rial endo cardi tis caus ed by MCCCLXX. 78 | P a g e MCCCLXXV. MCCCLV.

discontinue infusion . ext ravasation.MCCCLXVI.V. and thrombophl ebitis. If MCCCLXXXIV. infusion site for evidence of MCCCLXXXII. pain. ten derness. especially if patient has renal impairment or takes an aminoglyco side. ext ravasation occurs. MCCCLXXX. Causing cell wall lysis and cell death MCCCLXVII. MCCCLXXXIII. MCCCLXXXI. including necrosis. •O bserve I. 79 | P a g e creatinine and BUN levels during therapy.

MCCCLXXXVI.MCCCLXXXV. RATIONA LE MCCCXCVIII. MCCCXCII. NURSING INT ERV MCCCXCVII. EVALUATI ON . PLANNIN G MCCCXCVI. DIAGNOS IS MCCCXCIV. MCCCXC. INFEREN CE MCCCXCV. im mediately and notify prescriber. CUES 80 | P a g e Nursing Care Plan MCCCXCIII. MCCCXCI.

Af ter 30 min s. MCDXIII. of nurs ing inter vent ion the clien t will repo rt that pain has less en from the ENT ION MCDXXVIII.1 hr. Independ ent: MCDXXIX. of nurs ing inter vent ion the clien t repo rted that pain has bee n less . MCDXVI. MCDXVIII. A cute pain relat ed to infla mm ator y resp onse s from infla mm atio n MCDXII. MCDXXXVIII. -To esta blish base line para met er.“ mas akit ang mat a ko “ MCDII. To pro mot e nonphar mac olog ical pain man age men MCDLII. MCDXXXI. tem p.S> MCDI. MCDXXXIX. > R81 | P a g e MCDX. Short Ter m: MCDXXIV. > PRigh t eye MCDV. MCDXXI. MCD. Endopthal miti s MCDXIV. MCDIII. O > MCDIV. MCDXIX. Short ter m: MCDLIII. Inflammat ory resp ons e MCDXX. MCDXXIII. -Provide com fort mea sure s and quie t envi ron men MCDXXXVII. After 30 min s. -Monitor skin colo r. MCDXV. and v/s. > QShar p MCDVI.MCCCXCIX. MCDXL. Inflammat ion of insid e the eye MCDXVII.1 hr. MCDXI. MCDXXX. > S8/10 MCDVII.

MCDXXXIII. watc hing T. Acute Pain pain scal e of 8/10 4/10 . MCDXLV.Nonradi atin g pain MCDVIII. MCDXLI. t.V. >I rrita ble 82 | P a g e MCDXXII. Long Ter m: MCDXXVII. read ing MCDXLII. MCDLV. MCDXLIII. L ong Ter m: MCDLVI. MCDXLVIII. -To pro mot e nonphar mac olog ical pain man age men t. MCDXXV. MCDXXVI. MCDLIV. MCDXLVI. MCDXLIV. >TCont inou s MCDIX. en from the pain scal e of 8/10 4/10 . MCDXXXII. -Instruct and enc oura ge use of rela xati on tech niqu es such as focu sed brea thin g. Af ter 8 hour s of nurs ing inter vent ion the clien t gath ered . After 8 hour s of nurs ing inter vent ion the clien t will gath er som e t.. MCDXLVII.

MCDLI.infor mati on on how to dive rt pain . boo ks and liste ning to mus ic. Adm inist er eye drop s med icati ons as orde red by the 83 | P a g e MCDXLIX. MCDL. MCDXXXV. To less en pain . MCDXXXIV. Depende nt: MCDXXXVI. . som e infor mati on on how to dive rt pain .

DIAGNO SI S MCDLIX. EVALUAT IO N . RATION AL E MCDLXIII. NURSIN G INT MCDLXII. CUES 84 | P a g e MCDLVIII. MCDLVII. PLANNI NG MCDLXI. IN FERENCE MCDLX.phys ician .

-To be aw are of the un der lyi ng ca use . Hy perglycemi a-induced intramural pericyte d eath and thickening of the basem ent membrane MCDLXXXIII. MDIX. MDXII. >Lack of 85 | P a g e MCDLXXVI. Disturbe d sen sor y per ce pti on rel ate d to un der lyi ng co ndi tio n– Dia bet MCDLXXVIII. MDV. Short Ter m: MCDXCVII. MCDLXXXV. MCDLXXVII. of nur sin g int erv ent ion clie nt will ide ntif y ext ern al fac ER VE NTI ON MDII. MCDLXVIII. Ide ntif y clie nt with con diti on that affe cts sen sing . MCDLXXXI. of nur sin g inte rve ntio n clie nt ide nti fied ext ern al .MCDLXIV. le ad to incompete nce of the vascular walls MCDXCVI. MCDLXXXII. O> MCDLXIX.S hor t ter m: MDXVII. MDXI. S> MCDLXVI. A fter 2-4 hrs.Ind epe nde nt: MDIII. After 2-4 hrs. MDX. MCDLXV. Di abetes Mellitus MCDLXXX. MCDLXXXIV. To ass ess the de gre e of MDXVI. MDIV. “ hindi na ma ka kit a an g ka na n ko ng ma ta “ MCDLXVII. Eval uat e MDVIII. MCDLXXIX.

MDXIV. MDVII. MCDXCI. >Irritabil ity MCDLXXII. Assi st clie nts/ SO to lear n effe ctiv e way s of copi ng with and im pai rm ent . MCDLXXXVI. >Unable to vis ual ize (ri gh t ey e) 86 | P a g e es me llit us as evi de nc ed by reti no pat hy. Long Ter m: MD. MCDXCII. MCDLXXI. Re tinopathy MCDXCIII. of . (vis ual acui ty) MDVI. Di sturbed sensory perception (visual) tor s tha t con trib ute to alt era tio ns in sen sor y abil itie s. MCDLXXXVII. >Deviati on of ey e MCDLXXIV. MDXV. MCDLXXV. MDXIX. MDXVIII. MCDXCIV. MCDXCV. MCDXCVIII. Aft er 8 hrs.ey e co nt act MCDLXX. To be aw are of co pin g skil ls on bot h par tie s ( cl ien t an d fact ors tha t con trib ute to alte rati ons in sen sor y abil itie s. A fter 8 hrs. of sen sor y awa ren ess. MCDLXXIII. ch ange the formation of the bloodretinal barrier MCDLXXXIX.L on g Ter m: MDXX. MCDXCIX. MCDXC. MDXIII. MCDLXXXVIII.

. 87 | P a g e ma nag ing sen sor y dist urb anc es and anti cipa ting sen sor y defi cits. SO ) nur sin g inte rve ntio ns clie nt rec ogn ize d and co mp ens ate d for sen sor y imp air me nt.nur sin g int erv ent ion s clie nt will rec ogn ize s and co mp ens ate for sen sor y imp air me nt. MDXXI. MDI.

MDXXII. PLANNIN G MDXXVII. INFEREN CE MDXXVI. DIAGNOS IS MDXXV. EVALUATI ON . MDXXIII. RATIONA LE MDXXIX. NURSING INT ERV ENT ION MDXXVIII. CUES 88 | P a g e MDXXIV.

MDLXVI. Short Ter m: MDLXIV. 89 | P a g e MDXLII. Long Ter MDLXVIII.g. -Sleep prob lems MDLXXXVIII.Lack of Slee MDLXIII. MDXXXI. MDLXXXII. MDLV.Asse ss slee p patt ern dist urba nces that are asso ciat ed with the envi ron men t MDLXX. MDLXXI. -High perc enta ge of slee p dist urba nce can affe ct the reco very of the clien t. Independ ent: MDLXIX. MDL. “ nahi hira pan ako ng mat ulog dahi l may a’tmay a pina pata kan ako sa mat a“ MDXXXIII. Di abet es Melli tus MDXLVI. Af ter 2-4 hrs. MDXCI. MDXLIII. S> MDXXXII. of nurs ing inter vent ion clien t achi eve d opti mal amo unt of slee p. MDXC. Inter rupti ons MDLII. MDLXXX. MDLXV. MDXLV. (e . MDXLVIII. MDLXXXI. MDXLVII. Hospitaliz atio n MDXLIX. MDLI. L ong Ter . MDXXXIV. med icati ons Q1) MDLIII. Di stur bed slee p patt ern relat ed to hos pital izati on MDXLIV. of nurs ing inter vent ion clien t will achi eve opti mal amo unt of slee p. After 2-4 hrs. MDLIV.Iden tify pres MDLXXIX.MDXXX. Short Ter m: MDLXXXIX.

MDLXXII. MDXLI. MDLXII. can aris e from inter nal and exte rnal fact ors. >Irritabilit y MDXXXVIII. >restlessn ess MDXL. -Helps clari fy clien t’s perc epti on of slee p qua ntity m: MDXCII. m: MDLXVII. of nurs ing inter vent ions clien t iden tifie d indi vidu ally appr opri ate inter vent ions to pro mot e slee . -Listen to repo rts of slee p qual ity. MDLXXXV. >Presence of dark circl e und er the eyes (eye bag s) MDXXXVI. MDLXXXIII. Di stur bed Slee p Patt ern MDLX. After 8 hrs. After 8 hrs. MDLVII. 90 | P a g e p MDLVI. MDXXXVII. of nurs ing inter vent ions clien t will iden tify indi vidu ally appr opri ate inter vent ions to pro mot e slee p. MDLVIII. MDLIX. MDLXI. MDLXXV. MDLXXIII. MDLXXXIV. MDLXXVI. enc e of fact ors kno wn to inter fere with slee p.O> MDXXXV. MDLXXIV. MDXXXIX.

MDLXXXVI. cha ngin g dam p line ns or gow n. .MDLXXVII. -To pro mot e phys ical com fort. MDLXXXVII. 91 | P a g e and qual ity. p. MDXCIII. -Provide bedt ime care such as strai ghte ning bed she ets. MDLXXVIII.

INFERENC E MDXCVII. DIAGN O S I S MDXCVI. PLANNIN G MDXCVIII.MDXCIV.EVA LUA TIO N . NURSING INTER VENTI ON MDXCIX. RATIONA LE MDC. CUES 92 | P a g e MDXCV.

To enh anc e clien t’s abili MDCLX. MDCXL. “ hin di ko na ma ga wa an g mg a ba ga y na gus to kon g ga win da hil na hihi 93 | P a g e MDCXIII. Independen t: MDCXXXVIII. MDCXIV. MDCXXI. MDCLII. MDCLI. MDCXVIII. Provide enough MDCXLVII. MDCXXXIX. MDCII. MDCXXII. MDCLIII. Short Ter m: MDCLXI. of nurs ing inter vent ion clien t repo rted decr ease in acti vity intol eran ce with enh anc ed . After 3 hrs. -Provide health teachin g on the client regardi ng the organiz ation and time manag ement techniq ue to prevent while on activity. MDCXVI. Short Ter m: MDCXXXIII. Activity Intole rance MDCXXVI. MDCL. MDCXXV. MDCXXIV. Retinopath y MDCXX. -To prov ide ade quat e kno wled ge on the clien t. S > MDCIII.MDCI. of nur sing inte rve ntio n clie nt will rep ort dec reas e in acti vity into lera nce with enh MDCXXXVII. After 3 hrs. MDCXIX. Diabetes Mellit us MDCXVII. MDCXXXII. MDCXLIX. MDCXLVIII. Activity in to le r a n c e re la te d to p re s e n t c o n di ti o n MDCXV. Unable to visua lize MDCXXIII.

rap
an
na
ako
ng
ma
kak
ita“
MDCIV.
MDCV. O
>
MDCVI. >
Tir
ed
faci
al
exp
res
sio
n
MDCVII.
MDCVIII.
>Uncomf
ort
abl
e
MDCIX.
MDCX. >
Wo
94 | P a g e

MDCXXVII.
MDCXXVIII.
MDCXXIX.
MDCXXX.
MDCXXXI.

anc
ed
ene
rgy
and
the
pati
ent
will
part
icip
ate
willi
ngly
in
nec
ess
ary
or
desi
red
acti
viti
es.
MDCXXXIV.
MDCXXXV.
Long
Ter
m:

air
coming
from
the
electric
fan or
from
the
window.
MDCXLI.
MDCXLII.
-Develop and
adjust
simple
activity
like
brushin
g his
teeth.
MDCXLIII.
MDCXLIV.
-Assist client
with
activity.
MDCXLV.
MDCXLVI.

ty to
parti
cipa
te in
acti
vity.
MDCLIV.
MDCLV. To
mon
itor
clien
ts
resp
ond
to
acti
vitie
s.
MDCLVI.
MDCLVII.
-To
prev
ent
over
exer
tion.
MDCLVIII.

ener
gy
and
the
pati
ent
parti
cipa
ted
willi
ngly
in
nec
essa
ry or
desi
red
acti
vitie
s.
MDCLXII.
MDCLXIII.
Long
Ter
m:
MDCLXIV.
After 8
hrs.

rrie
d
MDCXI.
MDCXII.

95 | P a g e

MDCXXXVI.
After 8
hrs.
of
nur
sing
inte
rve
ntio
ns
clie
nt
will
use
ide
ntifi
ed
tec
hni
que
s to
enh
anc
e
acti
vity
tole
ran
ce.

-Promote
comfort
measur
es on
the
activity.

MDCLIX.
-To protect
clien
t
from
injur
y.

of
nurs
ing
inter
vent
ions
clien
t
used
iden
tifie
d
tech
niqu
es
to
enh
anc
e
acti
vity
toler
anc
e.

MDCLXV.
MDCLXVI.
CUES

96 | P a g e

MDCLXVII.
DIAGNO
SI
S

MDCLXVIII. IN
FERENCE

MDCLXIX.
PLANNI
NG

MDCLXX.
NURSIN
G
INT
ER
VE
NTI
ON

MDCLXXI.
RATION
AL
E

MDCLXXII.
EVALUAT
ION

MDCCXXI. -Assess gen eral stat us of the clie nt. incompete MDCLXXVII. at MDCXCIII. MDCCXLVII. to MDCXCVI. MDCLXXXVI. Le “ ad to MDCLXXVI. MDCCXIX. MDCLXXXVIII. After 8 . Ch su ange the ali formation 97 | P a g e MDCCXII. Indepen den t: MDCCXVIII. MDCCXXXI. MDCCXXXII. a MDCXCIV. nce of the O> vascular MDCLXXVIII. MDCCXXXIII. abetes S> Risk for Mellitus MDCLXXV. -To det er mi ne the lev MDCCXLV. inj MDCLXXXIX. MDCCXX. MDCCXV. na rel MDCXCI. Hy m ate perglycemi ak d a-induced ak to intramural ita pre pericyte d an se eath and g nt thickening is co of a ndi the basem ko tio ent ng n membrane m MDCXCII. After 2-3 hrs. -Assess mo od copi ng abili ties . of nur sing inte rve ntio n clie nt was free fro m inju ry. Long Ter m: MDCCXLIX. Short Ter m: MDCCXLVI. of nur sin g inte rve ntio n clie nt will be free fro m inju ry.MDCLXXIII. Long Ter m: MDCCXVII. walls >unable MDCXCV. After 2-3 hrs. Short Ter m: MDCCXIII. Di MDCLXXIV. -To det er mi ne clie nts con diti on tha t ma y cau se inju ry. “ hindi ury MDCXC. MDCCXLVIII. MDCLXXXVII. per son alit y MDCCXXX. vi MDCXCVII. MDCCXIV.

MDCXCIX. MDCCXXXV. MDCLXXX. MDCCXLIII. MDCCXXXVIII. After 8 hrs. MDCCXXXVII. Da mage to Retina MDCCIV. -To det er mi ne cau se of inju ry. >Irritabl e MDCLXXXIII. MDCCXXXIV. >rednes s (ri gh t ey e) MDCLXXXI. -Assess envi ron me ntal fact ors that ma y lea d to inju ry. MDCCIII. MDCCIX. 98 | P a g e of the bloodretinal barrier MDCXCVIII. MDCCXXIV. MDCCXXXIX. MDCCVI. MDCLXXXII. MDCCXXXVI. -To lessen the hrs. of nur sing inte rve ntio ns clie nt ver bali zed his und erst and ings reg ardi ng of indi vidu al fact ors that con . MDCCXXII. MDCCXVI. MDCCII. MDCCXLIV. MDCCXL. MDCLXXXV. MDCCXLI. MDCCXLII. MDCCV. Ri sk for Injury MDCCX. MDCC. MDCCXXIII. MDCLXXXIV. MDCCVIII. MDCCXI.ze (ri gh t ey e) MDCLXXIX. el of coo per ati on. Un able to visualize MDCCVII. Retinop athy MDCCI. of nur sin g inte rve ntio ns clie nt will ver bali ze und erst and ing of indi vid ual fact ors tha t styl es that ma y res ult in car eles sne ss.

99 | P a g e MDCCXXV. MDCCXXVII. saf e en vir on me nt an d pro mo te clie nts co mf ort. MDCCXXIX. . risk for inju ry. -Monitor V/S MDCCXXVIII. Promoting clie nts safe ty by: MDCCXXVI.con trib ute to pos sibil ity of inju ry. trib ute to pos sibil ity of inju ry. -Providing mat eria ls to pre ven t fro m inju ry.

  Exercise can help keep your blood sugar level steady. MDCCLV. These steps will help keep your blood sugar level closer to normal. MDCCLX. MDCCLII. Stress the importance of compliance to prescribed medication and never stop the medication abruptly.  Encourage the client to resume tolerable daily activities which achieving and maintaining an optimum level of wellness and health. DISCHARGE PLAN MDCCLI. MDCCLVII. Blood sugar monitoring Healthy eating Regular exercise Diabetes medication or insulin therapy MDCCLXI. Exercise MDCCLVI. Exercise for at least 30 minutes. MDCCLIX.  MDCCLIV.MDCCL. Health Teaching  Emphasize the importance of hygiene and hand washing to prevent infection. MDCCLVIII.  Remember that physical activity lowers blood sugar. Treatment  Monitor blood glucose  Encourage the patient to seek nearest hospital as soon as possible if symptoms are observed and cannot be relieved by medication. 5 days a week.  Advice the patient. and help you lose weight. 100 | P a g e . as well as the significant others that medication  should be taken as prescribed by the physician.  Advice patient to comply prescribe medication.      Instruct the patient to eat well-balanced diet. Medication MDCCLIII. which can delay or prevent complications. decrease your risk of heart disease.

Make a food distribution table. whole grain breads. = 170. Eat less salt: Limit foods that are high in sodium (salt). OPD MDCCLXIV. and height of 5’7. Pseudophakia OU. MDCCLXXII. A case of 53 year old male with a diagnosis of Endopthalmitis OD. MDCCLXXIV.MDCCLXII. Eat low-fat foods: Choose foods that are low in fat. Keep track of carbohydrates: Your blood sugar level can get too  high if you eat too many carbohydrates in 1 meal or snack.54 MDCCLXXVI. such as soy  sauce. MDCCLXVIII. Some  examples are skinless chicken and low-fat milk.    Diet as Tolerated Eat a well balanced diet. = 67 x 2. potato chips. Compute for TER (Total Energy Requirement). Compute for DBW (Desirable Body Weight). DBW = 5 x 12 = 60 + 7 MDCCLXXV. Compute for the CHO. and beans. MDCCLXVI. and soup. Eat high-fiber foods: Foods that are a good source of fiber include vegetables. MDCCLXV. Do not add salt to food you cook. MDCCLXIII. Diet MDCCLXVII. CHON and FAT requirement per day. Plan a menu. T/C DM Retinopathy OU.  Advice client to have a follow up check-up with his attending physician. MDCCLXXI. MDCCLXX. Actual weight of 59 kg. Diet Meal Plan Endodthalmitis MDCCLXXIII. Make a food exchange table.  Emphasize the importance and benefits of following the scheduled dates of checkup to prevent further complications. MDCCLXIX.18 – 100 101 | P a g e .

MEASU CHO R 2 E 6 5 g r.70)2 MDCCLXXXIII.5 or 256 gr.5 ÷4 = 66. BMI = 59 kg. FAT = 1770 x 25% = 442. MDCCC. MDCCCII. (Underweight) MDCCLXXXVI. MDCCXCIX.16 or 50 gr.4 MDCCLXXXV. MDCCCIII. FOOOD EXCHANGE TABLE MDCCXCVIII. MDCCXCV. = 1770 kcal MDCCXC. MDCCLXXXI. 102 | P a g e MDCCCI. CHON 6 5 g r. TER = (Actual weight x Activity) MDCCLXXXVIII. = 17. 3.5 ÷9 = 49. = 70. MDCCXCVI. MDCCXCII.35 kg. CHON = 1770 x 15 % = 265. FAT 5 0 g r. MDCCLXXXII.MDCCLXXVII. MDCCLXXX. CHO = 1770 x 60% = 1062 ÷4 = 265. = 59 kg. MDCCXCIII. (1.18 – 7.162 kg. MDCCXCIV. ENERG Y 1 7 7 0 k .018 MDCCLXXIX.375 or 65 gr.5 MDCCLXXXVII. = 63.18 – 10% MDCCLXXVIII. MDCCXCVII. = 70. MDCCLXXXIV. MDCCXCI. = (59 x 30) MDCCLXXXIX. Normal BMI = <18.

MDCCCXXIII. MDCCCLXII. MDCCCLIII. MDCCCLXXI. MDCCCLX. Meat 3 MDCCCXL.MDCCCIV. MDCCCXLIII. 96 MDCCCXVIII. 161 14 700 MDCCCXXXVI. 271 66 1780 FOOD DISTRIBUTION TABLE MDCCCLXI. MDCCCLXVII. 40 160 MDCCCXXIV. 24 16 10 250 MDCCCXXX. MDCCCXLI. - c a l. MDCCCXLVII. Fruits 4 MDCCCXXII. MDCCCLXIII. MDCCCXXV. MDCCCXVII. MDCCCIX. - MDCCCXV. Vegeta 6 b l e B MDCCCXVI.MDCCCXXXVIII. BREAK LUNCH DINNE SNACK SNACK F R A P A M M S T MDCCCLXVI. Rice 7 MDCCCXXXIV. MDCCCLXIV. MDCCCLV. MDCCCLI. 24 18 258 MDCCCXLII. 18 MDCCCVII. Vegeta 6 b l e A MDCCCX. MDCCCL. Fat 4 MDCCCXLVI. Vegeta 4 2 b l e A 103 | P a g e . MDCCCXX. MDCCCV. Total MDCCCLVIII. MDCCCXXXV. MDCCCLVII. Milk 2 MDCCCXXVIII. 6 MDCCCXIV. MDCCCXXXIX. MDCCCXXVII. MDCCCLXX. MDCCCXLIX. 18 MDCCCXIII. 10 40 MDCCCLIV. MDCCCXXXI. MDCCCXLIV. 20 180 MDCCCXLVIII. MDCCCVI. MDCCCXXXIII. MDCCCXXXII. MDCCCXXXVII. MDCCCLXVIII. MDCCCXIX. MDCCCLXV. MDCCCXLV. MDCCCXXI. Sugar 2 MDCCCLII. 96 MDCCCXII. MDCCCLVI. MDCCCXXIX. MDCCCXXVI. MDCCCLXIX. 6 MDCCCVIII. MDCCCXI. MDCCCLIX.

1 MBS Milk Fish MCMXX. Milk 1 1 MDCCCXC. MDCCCLXXX. 1 Medium size orange MCMXXI. MCMVII. MCM. Sugar 1 1 MCMXIV. BREAKFAST MCMXVII. MDCCCLXXXII. MCMV. Rice 2 2 2 1 MDCCCXCVI. MDCCCLXXIV. MCMXIII. Meat 1 1 1 MCMII. MDCCCXCIX. Fat 1 1 1 MCMVIII. MDCCCXCII. MDCCCXCV. 1 C Cooked Rice MCMXIX. 1 Cup Milk (4 Teaspoon of Milk) MCMXXII.MDCCCLXXIII. MCMX. 1 C Toge 104 | P a g e .MDCCCLXXII.MDCCCLXXXVII. MCMVI. MDCCCLXXXIX. MDCCCLXXVI. MCMIV. MDCCCXCVII. MDCCCLXXIX. MDCCCXCIV. MCMXVI. MDCCCXCVIII. MCMXI. MCMIX.MDCCCLXXXIII. 1 Teaspoon Brown Sugar MCMXXIII. Fruit 1 1 1 1 MDCCCLXXXIV. Vegeta 2 2 2 b l e B MDCCCLXXVIII. LUNCH MCMXXV. MDCCCXCIII. PLAN A MENU MCMXV. MDCCCLXXV. MDCCCLXXVII. MDCCCLXXXI. MCMXXIV. MDCCCXCI. Sinabawang Gulay - 1 1 1 1 1 1 C Squash fruit C Malunggay Leaves Okra Meduim Eggplant C Sitaw C Kangkong Leaves MCMXVIII. MDCCCLXXXVIII. MCMIII. 1 MCMI. MCMXII. MDCCCLXXXVI. MDCCCLXXXV.

SNACK PM MCMLI. 1 Medium size Banana MCMXXX. MCML.MCMXXVI. 1 Teaspoon Brown Sugar MCMXLV. 1 C Carrots MCMXXXVIII. MCMXXXIII. MCMXXXV. MCMXXXIV. 1 C Green beans MCMXXXVII. 1 C Cabbage MCMXXXIX. 1 MBS Pork MCMXLI. 1 C Carrot MCMXXVII. MCMXLVI. ½ Mango MCMXLIII. DINNER MCMXXXVI. MCMXXXII. 1 C Cooked Rice MCMXLII. SNACK AM MCMXLVII. 1 C Cooked Rice MCMXXIX. 1 MBS Chicken MCMXXVIII. 1 Cup Milk (4 Teaspoon of Milk) MCMXLIV. ½ C Lugaw MCMXLVIII. 1 Medium size apple 105 | P a g e . 1 C Chayote MCMXL. MCMXXXI. 1 Medium size egg MCMXLIX.

MCMLVIII. 106 | P a g e . Information and health teaching not only to the client who are suffering from this condition but also to the people who are interested to be aware in different conditions were imparted which lead to increase clients/ people awareness and knowledge with regards to her condition. certain problems and needs at the client were identified. Evaluation MCMLX. MCMLIII. Pseudophobia OU. MBS = Match Box Size MCMLVII. LEGEND: MCMLV. DM retinophasty including diagnostic examination. Through that assessment and data gathering. medical management needed and as well as the factors affecting the condition which may help the group and different people in handling properly this kind of condition that the student nurse may possible encounter again. C = Cup MCMLVI.MCMLII. Nursing care plan was established to improve client’s status and recovery. MCMLIX. The student nurse gained additional information about Endophthalmitis OP. MCMLIV.